Resources

Valens Research Weekly Equity Idea Highlight for July 18, 2018 – Gilead Sciences, Inc.

July 20, 2018

This week the Valens Research team highlights our most interesting equity insight from across our tools and our analysis.

Management’s success in operating their core business, intelligent acquisitions to drive growth, low market expectations and growing management confidence in their outlook are a diagnosis for equity upside

The market is expecting GILD to see significant declines in UAFRS-based (Uniform) ROA going forward, to the low end of peer profitability levels, from current best-in-class levels, with slower growth also. The company currently trades at the low end of historical valuations and the low end of peer valuations, highlighting the market’s pessimism.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email client.relations@valens-research.com.

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683